Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

VCA Inc (WOOF): Larry Robbins’ Glenview Capital Boosts Stake and Recommends Buing the stock

Larry Robbins’ Glenview Capital disclosed yesterday, in a Form 4 filed with the SEC, the acquisition of 4.11 million shares of VCA Inc (NASDAQ:WOOF)’s Common Stock. The stock was acquired through the exercise of in-the-money (or at-the-money) derivative securities, which expired on October 20, the date on which the transaction took place. Following this increase in its holdings in the company, the fund owns 12.8 million shares, which account for almost 15% of the company’s outstanding shares, and are worth more than half a billion dollars at current stock price.


Glenview Capital is a New York-based hedge fund founded by Larry Robbins in 2000. It currently has an equity portfolio worth more than $17 billion, mainly focused on healthcare stocks (36.2% of the total equity portfolio). Prior to founding Glenview Capital, Larry Robbins was a trader at Leon Cooperman’s Omega Advisors.

VCA Inc (NASDAQ:WOOF) is a $3.5 billion market cap provider of veterinary services and diagnostic testing to support veterinary care. The company also sells diagnostic imaging equipment and other medical technology products and related services to the veterinary market. Mr. Robbins has been bullish on VCA Inc (NASDAQ:WOOF) for a while now. A couple of months ago, we had reported a 45% increase in his bet on the company.  He reiterated his vote of confidence on last Tuesday’s Robin Hood Investors Conference, where he said that he likes this company because the pet hospitals industry is slowly recuperating after the hit it took during and after the financial crisis of 2008-2009.

In addition to Mr. Robbins, some analyst firms are also incentivizing inverstors’ confidence in VCA Inc (NASDAQ:WOOF). For instance, Zacks upgraded the company from a “neutral” rating to an “outperform” rating in a report released last week. The firm set $42.80 price objective on the stock; the current price barely surpasses $41.05 per share.

Moreover, several other institutional investors are also betting on VCA Inc (NASDAQ:WOOF). Ricky Sandler’s Eminence Capital last disclosed a 7% increase its exposure to the company over the second quarter of the year, and now owns 5.19 million shares, D E Shaw upped its stake by the same percentage, having last declared ownership of 1.28 million shares, and Daniel S. Och’s OZ Management added 63% to its holdings at the company over the period, taking its holdings to more than 2.85 million shares of Common Stock.

Glenview Capital has had amazing returns over the years, and is thus worth tracking. VCA Inc (NASDAQ:WOOF) is up 31.8% year-to-date, compared with the S&P 500’s 5.64%. In fact, Mr. Robbins returned 18% in the first half of the year. Impressive, right?

Disclosure: Javier Hasse holds no positions in any stocks or funds mentioned

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!